D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.34 CNY -1.82% Market Closed
Market Cap: 18.8B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Total Liabilities & Equity Peer Comparison

Comparables:
6160
603392
002252
300122
300896

Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Total Liabilities & Equity
ÂĄ1.5B
CAGR 3-Years
8%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Liabilities & Equity
ÂĄ41.1B
CAGR 3-Years
4%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Liabilities & Equity
ÂĄ15.7B
CAGR 3-Years
65%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Liabilities & Equity
ÂĄ32.4B
CAGR 3-Years
7%
CAGR 5-Years
23%
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Liabilities & Equity
ÂĄ54.8B
CAGR 3-Years
32%
CAGR 5-Years
43%
CAGR 10-Years
36%
Imeik Technology Development Co Ltd
SZSE:300896
Total Liabilities & Equity
ÂĄ6.9B
CAGR 3-Years
14%
CAGR 5-Years
71%
CAGR 10-Years
N/A

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
1.5B CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Total Liabilities & Equity amounts to 1.5B CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
19%

Over the last year, the Total Liabilities & Equity growth was -28%. The average annual Total Liabilities & Equity growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 8% over the past three years , 19% over the past five years .

Back to Top